The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease

2019 ◽  
Vol 494 ◽  
pp. 71-73 ◽  
Author(s):  
Leonardo Biscetti ◽  
Nicola Salvadori ◽  
Lucia Farotti ◽  
Samuela Cataldi ◽  
Paolo Eusebi ◽  
...  
CNS Spectrums ◽  
2008 ◽  
Vol 13 (S16) ◽  
pp. 34-35 ◽  
Author(s):  
Rachelle S. Doody

Today’s therapies must be put in the context of both currently available treatments as well as treatment trials with exciting potential for use in the near future. Current clinical trial methodologies do not allow for clear separation of symptomatic treatments from disease-modifying therapies; it may be unproductive to maintain this distinction given the current range of treatments available. A more currently relevant focus is added value. Therapies should aim to provide added value through incremental benefits above and beyond existing treatments, as well as enduring benefits.Alzheimer’s disease (AD) treatment guidelines are not used by physicians only. Healthcare payers often make use of these guidelines to delimit coverage. Cost concerns will also impact AD treatments after generic cholinesterase inhibitors are made available; it is widely believed that a great number of patients will switch to generics. Therefore, treatment guidelines must account for the possible adverse effects of switching therapies as well as the desirability of persistent treatment. There are many AD treatment guidelines, among them the American Academy of Neurology (AAN) Management of Dementia Guidelines, which are currently being revised. The Institute for the Study on Aging (ISOA) Management of Alzheimer’s Disease in Managed Care Guideline also presents a different approach for a different audience.The first step to creating evidence-based best practices guidelines is to determine what is meant by “evidence.” A system of classification exists for examining forms of evidence: Class I evidence is provided by one or more well-designed, randomized, controlled clinical trials, including overviews or meta-analyses of such trials. Class II evidence is provided by well-designed observational studies with concurrent controls; for example, case-control studies that generate hypotheses about epidemiologic associations. Class III evidence is provided by expert opinion, case series, case reports, and studies with historical controls.


2006 ◽  
Vol 14 (7S_Part_13) ◽  
pp. P719-P719
Author(s):  
Niccoló Tesi ◽  
Sven J. Van der Lee ◽  
Marc Hulsman ◽  
Iris E. Jansen ◽  
Najada Stringa ◽  
...  

2012 ◽  
Vol 8 (4S_Part_1) ◽  
pp. P14-P15
Author(s):  
Kristian Frederiksen ◽  
Anne-Mette Hejl ◽  
Ian Law ◽  
Steen Hasselbalch ◽  
Gunhild Waldemar

1997 ◽  
Vol 10 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Gerard J.M. Walstra ◽  
Saskia Teunisse ◽  
Willem A. van Gool ◽  
Hans van Crevel

It is widely accepted that excess disability (treatable coexisting physical disorders and psychiatric phenomena) is common in demented patients, and should be looked for carefully and treated properly, as it may result in improvement. This idea, however, does not state what investigations should be performed and what kind of improvement can be expected. Therefore, we studied prospectively in elderly outpatients with early Alzheimer's disease the prevalence of excess disability, the results of medication treatment, and the added value of investigations for diagnosis, treatment, and outcome after clinical examination. Outcome was assessed clinically and clinimetrically (using instruments with regard to cognition, disability in daily functioning, behavior, and caregiver burden). Excess disability was present in 66% of patients. Medication treatment was effective with regard to target symptoms, but (partial) reversal of dementia did not occur. Only blood tests produced unexpected results with consequences for treatment and outcome. Positive treatment effects often resulted from clinical examination only. We recommend blood tests in all patients; other investigations can be performed on clinical indication.


2017 ◽  
Vol 13 (7S_Part_21) ◽  
pp. P1024-P1025
Author(s):  
Francisca A. de Leeuw ◽  
Carel F.W. Peeters ◽  
Maartje I. Kester ◽  
Amy C. Harms ◽  
Thomas Hankemeier ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document